glp 1 makers RO OFFERS ELI LILLY'S FOUNDAYO™, THE NEWEST GLP-1 INNOVATION glp-1 drug makers Drugmakers are

If tirzepatide improves intestinal barrier function while reducing systemic inflammation through weight loss and metabolic improvement, it could theoretically address one of the upstream drivers of autoimmune disease activity

It is not available as a licensed medicine through the NHS, and it is not listed in the British National Formulary (BNF)

For this indication, it is well established, with cardiovascular outcomes data to support its use

Of these, 20 were assigned to receive 5 mcg of subcutaneous exenatide twice daily for 1 month, followed by 10 mcg twice daily for 11 months, while 24 were placed in the control group

Since the late 1990s, several pharmacological agents have received regulatory approval for chronic weight management in both Europe and the United States